Skip to main content

Table 1 Characteristics of Patients Comparing Pembrolizumab plus Chemotherapy or Pembrolizumab alone with Chemotherapy in Included Trials

From: First-line treatment for patients with advanced non-small cell lung carcinoma and high PD-L1 expression: pembrolizumab or pembrolizumab plus chemotherapy

Source

Histology

Therapeutic regimen

Chemotherapy Drug

No. of patients

NO. of response

PFSa(m)

HR for PFS

OSa(m)

HR for OS

Median Follow-up time (m)

Pem/Pem + Chemo

Chemo

Pem/Pem + Chemo

Chemo

KEYNOTE-021

2016, 2018

nonsquamous

Pem + Chemo vs. Chemo

AC

1) carboplatin (5 mg/ml/min Q3W)

2) pemetrexed (500 mg/m^2 Q3W)

20

17

16

6

NR

NR

NR

NR

23.9

KEYNOTE-189

2018

nonsquamous

Pem + Chemo vs. Chemo

AP or AC

1) cisplatin (75 mg/m^2 Q3W) or carboplatin (6 mg/ml/min Q3W)

2) pemetrexed (500 mg/m^2 Q3W)

132

70

81

16

NR

0.36 (0.25–0.52)

NR

0.42 (0.26–0.68)

10.5

KEYNOTE-407

2018

squamous

Pem + Chemo vs. Chemo

PC

1) carboplatin (6 mg/ml/min Q3W)

2) paclitaxel(200 mg/m^2 Q3W) or nab-paclitaxel (100 mg/m^2 Q1W)

73

73

44

24

8.0 vs. 4.2

0.37 (0.24–0.58)

NR

0.64 (0.37–1.10)

7.8

KEYNOTE-024

2016, 2017

suqamous and nonsquamous

Pem vs. Chemo

AP or AC or PC or GP or GC

1) cisplatin (75 mg/m^2 Q3W) or carboplatin (5-6 mg/ml/min Q3W)

2) pemetrexed (500 mg/m^2 Q3W) or paclitaxel (200 mg/m^2 Q3W) or Gemicitabine (1250 mg/m2 d1,8 of Q3W)

154

151

70

45

10.3 vs. 6.0

0.50 (0.37–0.68)

30.0 vs. 14.2

0.63 (0.47–0.86)

25.2

KEYNOTE-042

2018

suqamous and nonsquamous

Pem vs. Chemo

AC or PC

1) carboplatin (5-6 mg/ml/min Q3W)

2) pemetrexed (500 mg/m^2 Q3W) or paclitaxel (200 mg/m^2 Q3W)

299

300

118

96

7.1 vs. 6.4

0.81 (0.67–0.99)

20.0 vs. 12.2

0.69 (0.56–0.85)

12.8

  1. aData presented as “Pem/Pem + Chemo vs. Chemo”
  2. Abbreviation: Pem Pembrolizumab, Chemo Chemotherapy, NR Not Reported, HR Hazard Ratio, PFS Progression-free Survival, OS Overall survival;